BJC

British Journal of Cancer (2014) 111, 970–975 | doi: 10.1038/bjc.2014.371

Keywords: colorectal cancer; population screening; psychological outcomes

The psychological impact of participating in colorectal cancer screening by faecal immuno-chemical testing – the Australian experience

A Bobridge^{*,1}, P Bampton², S Cole³, H Lewis² and G Young²

¹School of Nursing & Midwifery, University of South Australia, Room 44, Level 6, Centenary Building, North Terrace, Adelaide, South Australia 5000, Australia; ²Flinders Centre for Innovation in Cancer Flinders University, Bedford Park, South Australia 5042, Australia and ³Bowel Health Service Repatriation General Hospital, Daws Road, Daws Park, South Australia 5041, Australia

Background: Occult blood-based colorectal cancer (CRC) screening may result in adverse psychological outcomes for participants. The aims of this study were to measure the psychological consequences of participating in screening at key points along the screening and diagnostic pathway, and examine variation over time within or between test outcome groups.

Methods: A total of 301 people (positives = 165, negatives = 136) aged 50–76 years were surveyed via validated psychological questionnaires after result notification, post colonoscopy (positives only) and 1 year following result notification.

Results: Negatives scored significantly higher in quality of life domains and lower state anxiety, anger and depression in comparison to positives both after result notification and at 1 year follow-up. Positives had significantly decreased state anxiety and depression at 1 year and improvement in HLoC power and reduced screening decision doubtfulness post colonoscopy. Positives experienced heightened CRC risk perception both after result notification and at 1 year follow-up in comparison to negatives, but reported less difficulty participating in ongoing screening.

Conclusions: In positives, increased anxiety and doubtfulness about the decision to screen declined over time. Lower CRC risk perception in negatives indicates the need for education to promote CRC screening participation.

Worldwide, colorectal cancer (CRC) is the third most common cancer in men and the second in women (WHO, 2010). To reduce the burden of CRC, various population screening programmes have been introduced (European Commission, 2010; Hoff and Dominitz, 2010; Ross, 2010) aimed at reducing morbidity and mortality through early detection. One of these programs – faecal immuno-chemical testing (FIT) can be achieved entirely through the postal system, with participants receiving a positive or negative result letter with follow-up advice.

However, studies have shown that those who test positive in such screening programmes experience elevated anxiety levels (Parker *et al*, 2002; Kapidzic *et al*, 2012). Possible distress may also arise from receiving a false positive result, undergoing a follow-up

colonoscopy or from anticipating an unfavourable diagnosis (Bowel Cancer Screening Pilot Monitoring and Evaluation Steering Committee, 2005; Wackerbarth *et al*, 2008).

Although the anxiety elicited from CRC screening is well established, less is known about the impact of this type of screening on quality of life (QOL), self-efficacy, cancer risk perception and screening decision making, all of which have been shown to influence future screening intentions and uptake (McQueen *et al*, 2008; Lewis *et al*, 2010; Dillard *et al*, 2012). Therefore, this prospective cohort study aimed to determine the short- and long-term psychological consequences of receiving a positive or negative result in FIT-based CRC screening programmes in Australia at key points along the screening and diagnostic pathway.

*Correspondence: Dr A Bobridge, E-mail: Amanda.Bobridge@unisa.edu.au

Received 25 February 2014; revised 15 May 2014; accepted 4 June 2014; published online 1 July 2014

© 2014 Cancer Research UK. All rights reserved 0007 – 0920/14

MATERIALS AND METHODS

Colorectal cancer population screening in Australia. Population screening was introduced in 2008 through the National Bowel Cancer Screening Program (NBCSP). The NBCSP Register sends eligible people a pre-invitation letter followed by an invitation pack, which includes an immunochemical test kit for detection of faecal occult blood. Participants collect two faecal samples, which are mailed to the programme pathology laboratory for analysis. Test results are sent to the participant and their nominated general practitioner, and positive participants are advised to undergo diagnostic colonoscopy. Approximately 6% of participants who undergo this form of screening test positive (Bowel Cancer Screening Pilot Monitoring and Evaluation Steering Committee, 2005).

Study eligibility criteria. Study participants had to be aged 50–74 years when they completed CRC screening. The positive group had a positive FIT following a NBCSP screening test and had been referred to metropolitan public hospitals for diagnostic colono-scopy. The negative group had a negative FIT through a public hospital co-ordinated population screening research programme, which followed exactly the same screening process as the NBCSP.

Ethics approval for this study was granted by the Southern Adelaide Clinical Human Research Ethics Committee.

Study design. Potential participants were mailed a study invitation, six questionnaires, a participant information sheet, an 'optout' form and a reply paid envelope. Completion and return of the questionnaires indicated consent. Those who did not opt out or reply were sent a second and third reminder after 4 and 6 weeks of the initial mail-out (Dillman *et al*,1993; Edwards *et al*, 2002).

Survey schedule. FIT positives were sent a set of questionnaires (1) after positive FIT result notification (ARN) but prior to undergoing colonoscopy; (2) after undergoing colonoscopy; and (3) at 12 months after the original result notification. FIT negatives were sent a set of questionnaires (1) after negative FIT result notification and (2) at 12 months after the original result notification. The average time from ARN to the first questionnaire being posted was 1–3 months, with the post colonoscopy questionnaire (for positive participants) sent 1–3 weeks after the procedure.

Questionnaires

- 1. *Demographic Information Survey*: age, gender, postcode (for Index of Relative Socioeconomic Disadvantage (IRSAD), Australian Bureau of Statistics, 2013), place of birth, first language, employment status and education level.
- 2. *Quality of Life Short-Form 36*: evaluates physical functioning, physical and emotional role limitations, vitality, mental health, social functioning, body pain, general health and health transition (Sharples *et al*, 2000; Basnov *et al*, 2009). Answers are weighted out of 100. Lower scores indicate poorer outcomes.
- 3. Anxiety & Depression Spielberger State-Trait Inventory: measures anxiety, curiosity, anger and depression traits as well as the participant's current state with respect to these indices (Spielberger, 2010). The higher the number, the worse the indice.
- 4. *Multi-Dimensional Health Locus of Control*: includes domains of 'internal control' and 'power' (measuring belief in personal control over health) and 'chance', 'doctor' and 'other people' (representing belief that other people or things control one's health) (Wallston *et al*, 1978). A higher aggregated score indicates stronger agreement with each domain.
- 5. Decision Evaluation Scale applied to CRC screening: uses a 5-point Likert scale to evaluate the participant's level of satisfaction with their decision to undertake CRC screening

(Stalmeier *et al*, 2005). A higher score equals stronger agreement with the item.

6. *Colorectal Cancer Risk*: uses a 7-point Likert scale to evaluate the participant's perception of CRC risk (risk perception), confidence in participating in screening (self-efficacy) and response to screening (response efficacy) (Levy *et al*, 2006). A higher number equals higher risk perception and efficacy.

Analysis. The sample size was calculated assuming 95% probability with 80% power to detect shifts in key outcome scores of 20%. All data were analysed using SPSS v19. As one objective of this study was to identify significant differences in outcomes between groups, analyses were conducted using paired and independent-sample *t*-tests. Chi-square analysis was performed on frequency data. Multivariate regression analyses were undertaken to identify psychosocial constructs jointly associated with test outcomes while controlling for differences in demographic factors between groups.

RESULTS

In all 520 questionnaires were sent ARN (positives = 305, negatives = 215), with 301 questionnaires returned (positives = 165, negatives = 136; response rate = 58%; see Figure 1).

Sample characteristics. The mean age of negatives was greater than that of positives, at 61.8 vs 59.5years (P = 0.009). The positive group had 43% females and 57% males, while the negative group had 53% females and 47% males (P = NS). The place of birth for the majority of participants was Australia (69% of positives, 76% of negatives) followed by the United Kingdom (23% of positives, 14% of negatives). Similar patterns in employment status and education qualifications were observed between groups. There was a significant difference between groups for the IRSAD, with more positives living in low IRSAD suburbs (45% vs 30%; P = 0.034). The few participants with English as second-language were in the positive group (P = 0.039). Multivariate regression analysis showed that differences in sample characteristics did not significantly influence study outcomes.

Quality of life. Positives showed no significant changes in QOL domains post colonoscopy or at 1 year relative to ARN. At both ARN and at 1 year, negatives demonstrated greater physical functioning (P = 0.016 and 0.017, respectively), vitality (P = 0.015 and 0.008), mental health (P = 0.026 and 0.049), social functioning (P = 0.036 and 0.004), general health (P = 0.025 and 0.036) and less role limitation related to emotional health problems (P = 0.012 and 0.020) compared to positives (Table 1).

Anxiety and depression. Positives experienced a significant improvement in the trait depression post colonoscopy (P=0.023) and improvements in state anxiety and depression at 1 year (P=0.050 and 0.041, respectively), while negatives had a significant improvement in the trait depression (P=0.000) at 1 year. ARN and 1-year comparison demonstrated significantly higher (worse) state anxiety (P=0.000 and 0.014), anger (P=0.005 and 0.004) and depression (P=0.011 and 0.000) in positives compared to negatives (Table 1).

Health locus of control. Post colonoscopy, positives demonstrated a significant improvement in the power domain (P = 0.042), indicating more self-control over their health. At 1 year, positives felt their health was less reliant on doctors (significant decrease in the doctor domain (P = 0.033)). There were no significant changes in the negative group or between groups ARN or at 1 year (Table 1).




Figure 1. Returned questionnaires, study withdrawals and opt-out numbers.

Decision evaluation. ARN, positives had greater doubtfulness about their screening decision (P=0.045) and felt less satisfied about the information they received (P=0.036) compared to negatives. Positives experienced a significant decrease in doubt related to their CRC screening decision post colonoscopy (P=0.004) and a decrease in wanting information about screening options at 1 year (P=0.022), while negatives experienced a significant decrease in satisfaction with information received (P=0.012; Table 1).

Colorectal cancer risk. Post colonoscopy, positives reported greater likelihood of developing CRC if they did not participate in screening (P = 0.005), and increased seriousness of suffering from CRC (P = 0.022), but less difficulty in participating in ongoing CRC screening (P = 0.012). Positives also experienced a significant improvement in self-efficacy post colonoscopy (P = 0.025), which decreased slightly at 1 year (P = 0.012). Negatives experienced no significant changes in cancer risk perception or self-efficacy at 1 year. ARN and 1-year comparisons demonstrated that negatives rated their likelihood of developing CRC, if they did not participate in screening (P = 0.002 and 0.000) and in comparison to the average person (P = 0.002 and 0.039), as lower relative to positives (Table 1).

DISCUSSION

We believe that this study is one of the most comprehensive assessments of the psychological impacts of FIT CRC screening, demonstrating that while a positive result does cause an element of anxiety, this improves over time. However, anxiety does remain higher than negatives, most likely associated with an increased perception of the risk of developing CRC. Undergoing screening is also associated with an increase in the autonomy of decision making and recognition that surveillance does reduce CRC risk, suggesting that overall there is perhaps a psychological benefit for FIT-positive participants.

Undergoing colonoscopy did not significantly change the QOL domains for positives, which is consistent with the QOL screening studies undertaken by Niv *et al* (2012) and Pizzo *et al* (2011). This is in contrast to a study by Taupin *et al* (2006) demonstrating statistically significant improvements in mental health, role limitations related to emotions and vitality post colonoscopy in FIT-positive participants. Together these studies strongly indicate that undergoing CRC screening is not detrimental to the screenee's QOL.

State anxiety, anger and depression were consistently lower in negatives compared to positives, although state anxiety did decrease in FIT positives post colonoscopy and at 1 year.

Cuestionnaire ARN Post col Pvalue ARN Pvalue ARN Short-Form 36 Stat Pvalue ARN Post col Pvalue ARN ARN Short-Form 36 Stat Stat Pvalue ARN Pvalue ARN Short-Form 36 Stat Stat Dist Stat	ARN 78 (±3. 52 (±1.) 82 (±1.) 87 (±2. 66 (±1.) 88 (±1.) 88 (±1.) 72 (±1.)	1-year P-value 1) 87 (±2.5) 0.016 3) 56 (±1.2) 0.034 3) 56 (±1.2) 0.034 3) 82 (±1.5) 0.076 3) 82 (±1.2) 0.034 3) 86 (±1.4) 0.0980 3) 80 (±1.4) 0.9484 3) 80 (±1.7) 0.484 3) 90 (±1.7) 0.484 4) 73 (±1.5) 0.279	ARN 76 (±3.2); 78 (±3 52 (±1.5); 52 (±1 77 (±2.3); 82 (±1 77 (±2.3); 82 (±1 76 (±3.5); 87 (±2 59 (±2.1); 66 (±1 74 (±1.6); 88 (±1 82 (±1.9); 88 (±1 82 (±1.9); 72 (±1)	P-value 1-year A)		
onnaire ARN Post col Pvalue Tyres Pvalue ARN Pvalue	A 78 52 87 87 87 88 88 88 88 88						
corm 36 tations - physical 76 (± 3.2) 72 (± 3.2) 0.186 75 (± 4.1) 0.522 tations - physical 32 (± 1.5) 51 (± 1.7) 0.927 55 (± 1.6) 0.160 tanistion 27 (± 2.3) 77 (± 2.3) 77 (± 2.3) 0.153 78 (± 3.3) 0.155 tations - emotional 26 (± 3.1) 36 (± 2.1) 36 (± 2.1) 0.290 tations - emotional 27 (± 2.3) 26 (± 2.3) 27 (± 2.3) 0.156 tations - emotional 26 (± 2.3) 26 (± 2.3) 26 (± 2.3) 0.138 66 (± 2.1) 0.817 tate/Trait Scale 74 (± 1.6) 18 (± 0.2) 17 (± 0.2) 0.092 16 (± 0.2) 0.046 tate/Trait Scale 17 (± 0.2) 0.022 16 (± 0.2) 0.046 tate/Trait Scale 17 (± 0.2) 0.023 11 (± 0.2) 0.046 tate/Trait Scale 17 (± 0.2) 16 (± 0.2) 0.046 16 (± 0.2) 0.046 <th co<="" th=""><th>72 55 87 87 88 88 88 88</th><th></th><th>76 (±3.2); 78 (±3.1) 52 (±1.5); 52 (±1.3) 77 (±2.3); 82 (±1.3) 76 (±3.5); 87 (±2.7) 59 (±2.1); 66 (±1.6) 74 (±1.6); 80 (±1.3) 82 (±2.3); 88 (±1.7) 67 (±1.9); 72 (±1.4)</th><th></th><th>1-year ARN</th><th>P-value</th></th>	<th>72 55 87 87 88 88 88 88</th> <th></th> <th>76 (±3.2); 78 (±3.1) 52 (±1.5); 52 (±1.3) 77 (±2.3); 82 (±1.3) 76 (±3.5); 87 (±2.7) 59 (±2.1); 66 (±1.6) 74 (±1.6); 80 (±1.3) 82 (±2.3); 88 (±1.7) 67 (±1.9); 72 (±1.4)</th> <th></th> <th>1-year ARN</th> <th>P-value</th>	72 55 87 87 88 88 88 88		76 (±3.2); 78 (±3.1) 52 (±1.5); 52 (±1.3) 77 (±2.3); 82 (±1.3) 76 (±3.5); 87 (±2.7) 59 (±2.1); 66 (±1.6) 74 (±1.6); 80 (±1.3) 82 (±2.3); 88 (±1.7) 67 (±1.9); 72 (±1.4)		1-year ARN	P-value
Itations - physical $76 (\pm 3.2)$ $72 (\pm 3.2)$ $75 (\pm 4.1)$ 0.522 $55 (\pm 4.1)$ 0.522 ransition $77 (\pm 2.3)$ $51 (\pm 1.7)$ 0.927 $55 (\pm 4.1)$ 0.160 functioning $77 (\pm 2.3)$ $51 (\pm 1.7)$ 0.927 $55 (\pm 2.3)$ 0.160 intritions - emotional $74 (\pm 1.6)$ $59 (\pm 2.1)$ 0.905 0.905 realth $59 (\pm 2.1)$ $59 (\pm 2.2)$ 0.916 $75 (\pm 2.1)$ 0.805 nealth $57 (\pm 1.9)$ $55 (\pm 2.0)$ 0.318 $66 (\pm 2.1)$ 0.817 netioning $82 (\pm 2.3)$ $82 (\pm 2.2)$ 1000 $81 (\pm 3.1)$ 0.206 netioning $82 (\pm 2.3)$ $82 (\pm 2.0)$ 0.138 $66 (\pm 2.1)$ 0.817 netioning $67 (\pm 1.9)$ 0.923 $11 (\pm 0.2)$ 0.944 $12 (\pm 0.2)$ 0.944 ression $16 (\pm 0.2)$ $17 (\pm 0.2)$ $13 (\pm 0.2)$ 0.945 0.947 ression $16 (\pm 0.2)$ 0.923 $11 (\pm 0.2)$ 0.945 0.945 ression $16 (\pm 0.2)$ 0.923 $16 (\pm 0.2)$ 0.945 0.945 ression $16 (\pm 0.2)$ 0.923 $16 (\pm 0.2)$ 0.945 0.945 ression $16 (\pm 0.2)$ 0.923 $16 (\pm 0.2)$ 0.945 0.945 ression $16 (\pm 0.2)$ 0.923 $16 (\pm 0.2)$ 0.923 \mathbf	78 52 87 87 88 88 88 88		76 (±3.2); 78 (±3.1) 52 (±1.5); 52 (±1.3) 77 (±2.3); 82 (±1.3) 76 (±3.5); 87 (±2.7) 59 (±2.1); 66 (±1.6) 74 (±1.6); 80 (±1.6) 82 (±2.3); 88 (±1.7) 67 (±1.9); 72 (±1.4)				
ansition $52 (\pm 1.5)$ $51 (\pm 1.7)$ 0927 $55 (\pm 2.0)$ 0.160 functioning $77 (\pm 2.3)$ $77 (\pm 2.3)$ 0614 $75 (\pm 3.3)$ 0290 realth $59 (\pm 2.1)$ $59 (\pm 2.1)$ 0464 $75 (\pm 2.3)$ 0015 realth $74 (\pm 1.6)$ $55 (\pm 2.3)$ $82 (\pm 2.3)$ 0216 0236 nctioning $57 (\pm 1.9)$ $55 (\pm 2.0)$ 0138 $66 (\pm 2.1)$ 0305 nething $57 (\pm 1.9)$ $55 (\pm 2.0)$ 0138 $66 (\pm 2.1)$ 0317 nething $17 (\pm 0.2)$ $18 (\pm 0.2)$ 0.164 $55 (\pm 2.0)$ 0.056 step $17 (\pm 0.2)$ $18 (\pm 0.2)$ $17 (\pm 0.2)$ 0.056 0.044 ression $16 (\pm 0.2)$ 0.023 $11 (\pm 0.2)$ 0.026 0.044 ression $16 (\pm 0.2)$ 0.023 $12 (\pm 0.2)$ 0.046 0.044 ression $16 (\pm 0.2)$	52 87 88 88 88 88 72 88		52 (±1.5); 52 (±1.3) 77 (±2.3); 82 (±1.3) 76 (±3.5); 87 (±2.7) 59 (±2.1); 66 (±1.6) 74 (±1.6); 80 (±1.3) 82 (±2.3); 88 (±1.7) 67 (±1.9); 72 (±1.4)	0.511 75 (±	75 (± 4.1); 87 (± 2.5)	0.014	
functioning77 (± 2.3)77 (± 2.3)77 (± 2.3)0.61475 (± 3.0)0.290itations - emotional59 (± 3.1)0.15378 (± 3.1)0.291seath74 (± 1.6)59 (± 2.0)0.91159 (± 2.0)0.036mettioning82 (± 2.3)82 (± 2.3)0.01366 (± 2.1)0.817heatih82 (± 2.3)65 (± 2.0)0.13866 (± 2.1)0.817heatin82 (± 2.3)52 (± 2.3)0.01366 (± 2.1)0.817heatin82 (± 2.3)17 (± 0.3)0.21617 (± 0.3)0.246heatin17 (± 0.3)17 (± 0.3)0.21612 (± 0.6)0.44perssion12 (± 0.3)17 (± 0.3)0.2160.464pression16 (± 0.2)0.19816 (± 0.6)0.464pression16 (± 0.2)0.19816 (± 0.6)0.464pression16 (± 0.2)0.10916 (± 0.3)0.426pression16 (± 0.2)0.12912 (± 0.3)0.426pression16 (± 0.2)0.12912 (± 0.3)0.426pression16 (± 0.2)0.1290.1290.426pression16 (± 0.2)0.1290.1290.426pression16 (± 0.2)0.1290.1290.426pression12 (± 0.3)0.02311 (± 0.3)0.023pression12 (± 0.2)0.1290.1290.464pression12 (± 0.2)0.1290.129 <td></td> <td></td> <td>77 (±2.3); 82 (±1.3) 76 (±3.5); 87 (±2.7) 59 (±2.1); 66 (±1.6) 74 (±1.6); 80 (±1.3) 82 (±2.3); 88 (±1.7) 67 (±1.9); 72 (±1.4)</td> <td></td> <td></td> <td>0.785</td>			77 (±2.3); 82 (±1.3) 76 (±3.5); 87 (±2.7) 59 (±2.1); 66 (±1.6) 74 (±1.6); 80 (±1.3) 82 (±2.3); 88 (±1.7) 67 (±1.9); 72 (±1.4)			0.785	
Itations - emotional $76 (\pm 3.5)$ $80 (\pm 3.1)$ 0.153 $78 (\pm 3.2)$ 0.053 realth $74 (\pm 1.6)$ $57 (\pm 2.0)$ 0.911 $59 (\pm 2.5)$ 0.298 nealth $74 (\pm 1.6)$ $82 (\pm 2.3)$ 0.031 $86 (\pm 2.1)$ 0.817 nealth $67 (\pm 1.9)$ $65 (\pm 2.0)$ 0.138 $66 (\pm 2.1)$ 0.817 nealth $67 (\pm 1.9)$ $65 (\pm 2.0)$ 0.138 $66 (\pm 2.1)$ 0.817 nealth $67 (\pm 1.6)$ 0.138 $66 (\pm 2.1)$ 0.817 nealth $17 (\pm 0.5)$ $18 (\pm 0.6)$ 0.246 nession $12 (\pm 0.3)$ $17 (\pm 0.3)$ 0.216 $12 (\pm 0.5)$ ger $12 (\pm 0.2)$ $17 (\pm 0.3)$ 0.216 $12 (\pm 0.5)$ 0.464 pression $16 (\pm 0.6)$ 0.241 $12 (\pm 0.2)$ 0.426 pression $16 (\pm 0.2)$ $17 (\pm 0.3)$ 0.216 $12 (\pm 0.2)$ 0.426 perssion $16 (\pm 0.2)$ $12 (\pm 0.2)$ 0.023 $11 (\pm 0.3)$ 0.426 pression $16 (\pm 0.2)$ $12 (\pm 0.2)$ 0.024 $12 (\pm 0.2)$ 0.041 pression $12 (\pm 0.2)$ $12 (\pm 0.3)$ 0.023 0.045 pression $12 (\pm 0.2)$ 0.129 0.129 0.266 perssion $12 (\pm 0.2)$ 0.024 0.041 pression $12 (\pm 0.2)$ 0.022 $11 (\pm 0.2)$ 0.042 pression $12 (\pm 0.2)$ 0.022 $12 (\pm 0.2)$ 0.024 pression $12 (\pm 0.2)$ 0.022 $12 (\pm 0.2)$ 0.026 <			76 (±3.5); 87 (±2.7) 59 (±2.1); 66 (±1.6) 74 (±1.6); 80 (±1.3) 82 (±2.3); 88 (±1.7) 67 (±1.9); 72 (±1.4)		75 (± 3.0); 82 (± 1.5)	0.017	
tealth nealth inctioning59 (± 2.1) $27 (\pm 1.6)$ 59 (± 2.3) $23 (\pm 1.7)$ 0.294 $0.67 (\pm 2.1)$ 0.208 0.0138 inctioning health $27 (\pm 1.6)$ $73 (\pm 1.7)$ 0.464 $75 (\pm 2.1)$ 0.805 sree $82 (\pm 2.3)$ $82 (\pm 2.3)$ 0.246 0.246 inctioning $67 (\pm 1.9)$ $65 (\pm 2.0)$ 0.138 $66 (\pm 2.1)$ 0.817 sree $17 (\pm 0.3)$ $17 (\pm 0.3)$ 0.216 $12 (\pm 0.5)$ 0.464 pression $12 (\pm 0.3)$ $17 (\pm 0.3)$ 0.216 $12 (\pm 0.6)$ 0.041 pression $16 (\pm 0.3)$ $17 (\pm 0.3)$ 0.216 $12 (\pm 0.6)$ 0.041 pression $16 (\pm 0.3)$ $17 (\pm 0.3)$ 0.226 $11 (\pm 0.3)$ 0.426 pression $16 (\pm 0.3)$ $17 (\pm 0.2)$ 0.023 $11 (\pm 0.3)$ 0.426 pression $16 (\pm 0.2)$ 0.023 $11 (\pm 0.3)$ 0.426 pression $16 (\pm 0.2)$ 0.023 $11 (\pm 0.3)$ 0.426 pression $16 (\pm 0.2)$ 0.023 $11 (\pm 0.3)$ 0.023 pression $16 (\pm 0.2)$ 0.023 $11 (\pm 0.3)$ 0.047 pression $16 (\pm 0.2)$ 0.023 $11 (\pm 0.3)$ 0.042 pression $12 (\pm 0.2)$ 0.023 $11 (\pm 0.3)$ 0.033 pression $12 (\pm 0.2)$ 0.023 $12 (\pm 0.3)$ 0.022 pression $12 (\pm 0.2)$ 0.023 $12 (\pm 0.3)$ 0.033 pression $12 (\pm 0.2)$ 0.022 $12 (\pm 0.2)$ 0.033 <			59 (±2.1); 66 (±1.6) 74 (±1.6); 80 (±1.3) 82 (±2.3); 88 (±1.7) 67 (±1.9); 72 (±1.4)			0.020	
retroning $74 (\pm 1.0)$ $75 (\pm 2.1)$ 0.404 $75 (\pm 2.1)$ 0.005 nectioning $67 (\pm 1.9)$ $65 (\pm 2.0)$ 0.138 $66 (\pm 2.1)$ 0.817 sreer $32 (\pm 2.3)$ $82 (\pm 2.3)$ $82 (\pm 2.3)$ 0.005 0.817 0.025 wiety $17 (\pm 0.5)$ $18 (\pm 0.7)$ 0.092 $16 (\pm 0.5)$ 0.044 pression $17 (\pm 0.3)$ $17 (\pm 0.3)$ $17 (\pm 0.3)$ 0.216 $12 (\pm 0.6)$ 0.041 pression $16 (\pm 0.2)$ $17 (\pm 0.2)$ $17 (\pm 0.3)$ 0.216 $10 (\pm 0.6)$ 0.041 pression $16 (\pm 0.2)$ $17 (\pm 0.2)$ $17 (\pm 0.3)$ 0.223 $11 (\pm 0.3)$ 0.426 pression $16 (\pm 0.2)$ $12 (\pm 0.3)$ $12 (\pm 0.2)$ 0.041 $12 (\pm 0.6)$ 0.041 pression $16 (\pm 0.2)$ 0.023 $11 (\pm 0.3)$ 0.426 0.426 pression $12 (\pm 0.3)$ $12 (\pm 0.2)$ 0.023 $11 (\pm 0.3)$ 0.426 pression $12 (\pm 0.$		(±1.7) (±1.7) (±1.5)	/4 (±1.0); 60 (±1.3) 82 (±2.3); 88 (±1.7) 67 (±1.9); 72 (±1.4)		59 (± 2.5); 67 (± 1.6) 7 E (+ 2.3); 60 (+ 1.4)	0.008	
menduality \mathbf{G} (±1.9) \mathbf{G} (±2.1) \mathbf{G} ((±1.5)	((±)c/ 070.0 +)ta 7200	(1.1 ±) 80 (1.2 ±) 61 (1.4 ±) 41 ±) 42 ±)	0.049	
reger State/Trait Scale xiety 17 (± 0.5) 18 (± 0.7) 0.092 16 (± 0.5) 0.050 ger 12 (± 0.4) 12 (± 0.3) 0.216 12 (± 0.5) 0.044 pression 16 (± 0.2) 17 (± 0.7) 0.198 16 (± 0.6) 0.041 pression 16 (± 0.2) 15 (± 0.2) 0.023 11 (± 0.3) 0.426 pression 16 (± 0.2) 15 (± 0.2) 0.041 24 (± 0.3) 0.043 pression 26 (± 0.2) 17 (± 0.3) 0.042 19 (± 0.3) 0.045 pression 26 (± 0.2) 13 (± 0.2) 0.022 0.033 21 (± 0.4) 0.453 pression 28 (± 0.2) 0.129 0.129 0.033 21 (± 0.4) 0.453 proved 28 (± 0.2) 0.022 0.033 20 0.026 2.6 (± 0.2) 0.044 proved 28 (± 0.2) 0.023 0.023 0.023 0.023 0.033 proved 28 (± 0.2) 0.026 2.6 (± 0.2) 0.033 0.026 0.041 0.045 0.046 </td <td></td> <td></td> <td></td> <td></td> <td>66 (±2.1); 73 (±1.5)</td> <td>0.036</td>					66 (±2.1); 73 (±1.5)	0.036	
xiety tiety17 (± 0.5)18 (± 0.7)0.09216 (± 0.5)0.056ger pression12 (± 0.3)12 (± 0.3)0.21612 (± 0.5)0.044pression16 (± 0.2)17 (± 0.3)0.19816 (± 0.5)0.041pression16 (± 0.2)15 (± 0.2)0.02311 (± 0.3)0.426pression16 (± 0.3)17 (± 0.3)0.02311 (± 0.3)0.426pression16 (± 0.3)17 (± 0.2)0.02311 (± 0.3)0.426pression26 (± 0.4)25 (± 0.4)0.46124 (± 0.5)0.058pression28 (± 0.4)21 (± 0.4)0.63821 (± 0.4)0.453pression21 (± 0.4)21 (± 0.4)0.63821 (± 0.4)0.033pople5 (± 0.2)13 (± 0.2)0.0320.033pople5 (± 0.2)0.1290.1290.033pople5 (± 0.2)0.1290.1290.033pople2.8 (± 0.1)13 (± 0.2)0.05662.6 (± 1.5)n Evaluation Scale1.7 (± 0.1)1.3 (± 0.1)0.3784.6 (± 0.1)n errore2.8 (± 0.1)3.0 (± 0.1)0.3762.6 (± 1.5)0.032ion with info2.8 (± 0.1)0.3782.6 (± 0.1)0.713ion with info2.8 (± 0.1)0.3784.6 (± 0.1)0.713is procedure2.6 (± 0.1)3.8 (± 0.1)0.7053.8 (± 0.1)0.713in flipoort if don't participa	-			-			
mession 12 (± 0.4) 12 (± 0.2) 0.216 12 (± 0.5) 0.444 pression 16 (± 0.2) 17 (± 0.1) 0.198 16 (± 0.6) 0.041 pression 16 (± 0.2) 15 (± 0.2) 0.023 11 (± 0.3) 0.426 Locus of Control 26 (± 0.4) 25 (± 0.4) 0.461 24 (± 0.5) 0.041 level 26 (± 0.4) 27 (± 0.4) 0.461 24 (± 0.5) 0.038 level 18 (± 0.3) 19 (± 0.3) 0.042 19 (± 0.3) 0.033 sople 26 (± 0.2) 0.363 21 (± 0.4) 0.6538 21 (± 0.4) 0.453 sople 5 (± 0.2) 0.362 6 (± 0.2) 0.042 13 (± 0.3) 0.033 sople 5 (± 0.2) 0.366 26 (± 0.1) 0.128 14 (± 0.1) 0.368 network 3.0 (± 1.3) 0.566 2.6 (± 1.5) 0.566 2.6 (± 1.5) 0.568 no with info 3.0 (± 1.3) 0.218 4.6 (± 0.1) 0.713 0.733 sk percedure 3.4 (+ 0.1) 3.8 (+ 0.1) 0.705 3.8 (+ 0.1) 0.713		14 (+0.4) 0.261	17 (+02) 15 (+04)	0.000 16 (+	16 (+05): 14 (+04)	0.014	
Dension16 (± 0.3)17 (± 0.7)0.19816 (± 0.6)0.041Pression16 (± 0.2)15 (± 0.2)0.19816 (± 0.6)0.041Locus of Control26 (± 0.3)17 (± 0.2)0.02311 (± 0.3)0.426Locus of Control26 (± 0.3)19 (± 0.3)0.06124 (± 0.5)0.0139Self28 (± 0.3)29 (± 0.3)0.04219 (± 0.5)0.139Self28 (± 0.3)20.04219 (± 0.3)0.04219 (± 0.5)0.139Self28 (± 0.3)20.04213 (± 0.3)0.04219 (± 0.5)0.033Bople5 (± 0.2)13 (± 0.2)0.04212 (± 0.3)0.033Bople5 (± 0.2)0.0206 (± 0.2)0.05626 (± 1.5)0.056In Evaluation Scale1.7 (± 0.1)1.3 (± 0.1)0.2041.4 (± 0.1)0.489I about decision2.8 (± 0.1)3.0 (± 1.3)0.2562.6 (± 1.5)0.022I about decision2.8 (± 0.1)3.0 (± 1.3)0.2662.6 (± 1.5)0.713I about decision2.8 (± 0.1)3.8 (± 0.1)0.7130.713I brood If don't participate in creasing3.4 (± 0.1)3.8 (± 0.1)0.7053.8 (± 0.1)0.701			12 (+0.4); 11 (+0.2)		12 (+0.5): 11 (+0.2)	0.004	
Intension 16 (+0.2) 15 (±0.2) 0.023 11 (±0.3) 0.426 Locus of Control 26 (±0.4) 25 (±0.4) 0.461 24 (±0.5) 0.058 13 (±0.3) 19 (±0.3) 0.461 24 (±0.5) 0.058 0.139 26 (±0.4) 25 (±0.4) 0.461 24 (±0.5) 0.058 0.139 21 (±0.4) 21 (±0.4) 0.638 21 (±0.4) 0.633 21 (±0.4) 0.453 21 (±0.2) 13 (±0.2) 0.042 13 (±0.2) 0.033 2003 0.033 eople 5 (±0.2) 13 (±0.2) 0.0461 24 (±0.3) 0.0566 26 (±1.5) 0.033 oblic valuation Scale 1.7 (±0.1) 1.3 (±0.1) 0.378 4.6 (±0.1) 0.46 (±0.1) 0.46 (±0.1) 0.46 (±0.1) 0.14 (±0.1) 0.14 (±0.1) 0.148 ion with info 2.8 (±0.1) 3.0 (±1.3) 0.0566 2.6 (±1.5) 0.022 0.022 ion with info 2.8 (±0.1) 0.378 4.6 (±0.1) 0.713 0.713 0.713 k perception 3.4 (±0.1) 3.8 (±0.1) 0.705 3.8 (±0.1)			16 (±0.3): 15 (±0.2)		16 (±0.6); 14 (±0.4)	0.000	
Locus of Control26 (± 0.4)25 (± 0.4)0.46124 (± 0.5)0.05818 (± 0.3)19 (± 0.3)0.04219 (± 0.5)0.13921 (± 0.4)21 (± 0.4)0.63821 (± 0.4)0.45321 (± 0.4)21 (± 0.4)0.63821 (± 0.4)0.45321 (± 0.2)13 (± 0.2)0.12912 (± 0.3)0.033eople5 (± 0.2)6 (± 0.2)0.0906 (± 0.2)0.094n Evaluation Scale1.7 (± 0.1)1.3 (± 0.1)0.0041.4 (± 0.1)0.489n evaluation Scale2.8 (± 0.1)3.0 (± 1.3)0.5662.6 (± 1.5)0.022ion with info2.8 (± 0.1)3.0 (± 1.3)0.5662.6 (± 1.5)0.022ion with info4.6 (± 0.1)3.0 (± 1.3)0.2662.6 (± 1.5)0.022ion with info4.5 (± 0.1)0.3784.6 (± 0.1)0.368icons of procedure4.5 (± 0.1)3.8 (± 0.1)0.7134.6 (± 0.1)0.713ik perception3.4 (± 0.1)3.8 (± 0.1)0.7653.8 (± 0.1)0.740			16 (+0.2); 10 (±0.3)		11 (± 0.3); 9 (± 0.2)	0.003	
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	-	-		-			
acple 18 (±0.3) 19 (±0.3) 0.042 19 (±0.5) 0.139 acple 21 (±0.4) 0.638 21 (±0.4) 0.633 0.139 acple 5 (±0.2) 13 (±0.2) 0.129 12 (±0.3) 0.033 about decision 5 (±0.2) 6 (±0.2) 0.090 6 (±0.2) 0.964 n Evaluation Scale 1.7 (±0.1) 1.3 (±0.1) 0.090 6 (±0.2) 0.964 about decision 1.7 (±0.1) 1.3 (±0.1) 0.090 6 (±0.2) 0.964 i about decision 2.8 (±0.1) 3.0 (±1.3) 0.566 2.6 (±1.5) 0.022 ion with info 2.8 (±0.1) 3.0 (±1.3) 0.566 2.6 (±0.1) 0.368 d cons of procedure 4.5 (±0.1) 0.713 0.218 4.6 (±0.1) 0.713 ik perception 3.4 (±0.1) 3.8 (±0.1) 0.705 3.8 (±0.1) 0.740	L	25 (+0.6) 0.280	26 (+0.4): 24 (+0.4)	0.103 24 (+	24 (+0.5): 25 (+0.6)	0.280	
21 (± 0.4) 21 (± 0.4) 0.638 21 (± 0.4) 0.453 eople 2 (± 0.2) 13 (± 0.2) 0.039 0.453 n Evaluation 5 (± 0.2) 6 (± 0.2) 0.090 6 (± 0.2) 0.094 n Evaluation Scale 5 (± 0.2) 6 (± 0.2) 0.090 6 (± 0.2) 0.044 n Evaluation Scale 1.7 (± 0.1) 1.3 (± 0.1) 0.004 1.4 (± 0.1) 0.489 about decision 1.7 (± 0.1) 1.3 (± 0.1) 0.004 1.4 (± 0.1) 0.489 io mith info 0 about options 2.8 (± 0.1) 3.0 (± 1.3) 0.566 2.6 (± 1.5) 0.022 ion with info 4.5 (± 0.1) 0.378 4.6 (± 0.1) 0.368 1.6 (± 0.1) 0.713 ic cons of procedure 4.5 (± 0.1) 0.218 4.6 (± 0.1) 0.713 1.7 1.7 ik porteition 4.6 (± 0.1) 3.8 (± 0.1) 0.705 3.8 (± 0.1) 0.713 1.7			18 (±0.3); 18 (±0.3)		19 (±0.5); 19 (±0.5)	0.327	
apple 12 (± 0.2) 13 (± 0.2) 0.129 12 (± 0.3) 0.033 apple 5 (± 0.2) 6 (± 0.2) 0.090 6 (± 0.2) 0.033 m Evaluation Scale 5 (± 0.2) 6 (± 0.2) 0.090 6 (± 0.2) 0.033 a bout decision 1.7 (± 0.1) 1.3 (± 0.1) 0.004 1.4 (± 0.1) 0.489 a bout options 2.8 (± 0.1) 3.0 (± 1.3) 0.566 2.6 (± 1.5) 0.022 ion with info 4.6 (± 0.1) 4.7 (± 0.1) 0.218 4.6 (± 0.1) 0.368 d cons of procedure 4.5 (± 0.1) 0.218 4.6 (± 0.1) 0.713 13 ik perception 3.4 (± 0.1) 3.8 (± 0.1) 0.005 3.8 (± 0.1) 0.940			21 (±0.4); 21 (±0.4)		21 (±0.4); 22 (±0.6)	0.083	
5 (±0.2) 6 (±0.2) 0.090 6 (±0.2) 0.964 1.7 (±0.1) 1.3 (±0.1) 0.004 1.4 (±0.1) 0.489 2.8 (±0.1) 3.0 (±1.3) 0.566 2.6 (±1.5) 0.022 4.6 (±0.1) 4.7 (±0.1) 0.378 4.6 (±0.1) 0.368 4.5 (±0.1) 4.7 (±0.1) 0.218 4.6 (±0.1) 0.713 3.4 (+0.1) 3.8 (+0.1) 0.218 4.6 (±0.1) 0.713		13 (+0.3) 0.223	12 (±0.2); 12 (±0.2)	0.962 12 (±	12 (±0.3); 13 (+0.3)	0.293	
1.7 (±0.1) 1.3 (±0.1) 0.004 1.4 (±0.1) 0.489 2.8 (±0.1) 3.0 (±1.3) 0.566 2.6 (±1.5) 0.022 4.6 (±0.1) 4.7 (±0.1) 0.378 4.6 (±0.1) 0.368 4.5 (±0.1) 4.7 (±0.1) 0.218 4.6 (±0.1) 0.713 3.4 (±0.1) 3.8 (±0.1) 0.705 3.8 (±0.1) 0.740		7 (±0.3) 0.187	5 (±0.2); 6 (±0.2)	0.133 6 (±	6 (±0.2); 7 (±0.3)	0.521	
1.7 (±0.1) 1.3 (±0.1) 0.004 1.4 (±0.1) 0.489 2.8 (±0.1) 3.0 (±1.3) 0.566 2.6 (±1.5) 0.022 4.6 (±0.1) 4.7 (±0.1) 0.378 4.6 (±0.1) 0.368 4.5 (±0.1) 4.7 (±0.1) 0.218 4.6 (±0.1) 0.368 3.4 (±0.1) 3.7 (±0.1) 0.218 4.6 (±0.1) 0.713							
2.8 (±0.1) 3.0 (±1.3) 0.566 2.6 (±1.5) 0.022 4.6 (±0.1) 4.7 (±0.1) 0.378 4.6 (±0.1) 0.368 4.5 (±0.1) 4.7 (±0.1) 0.218 4.6 (±0.1) 0.713 3.4 (±0.1) 3.8 (±0.1) 0.713	_	1.5 (±0.1) 0.618	1.7 (±0.1); 1.4 (±0.1)	0.045 1.4 (±	1.4 (±0.1); 1.5 (±0.1)	0.712	
4.6 (±0.1) 4.7 (±0.1) 0.378 4.6 (±0.1) 0.368 4.5 (±0.1) 4.7 (±0.1) 0.218 4.6 (±0.1) 0.713 3.4 (±0.1) 3.8 (±0.1) 0.713 3.8 (±0.1) 0.713			2.8 (±0.1); 2.9 (±0.1)	0.379 2.6 (±	2.6 (±1.5); 2.9 (±0.1)	0.108	
4.5 (±0.1) 4.7 (±0.1) 0.218 4.6 (±0.1) 0.713 3.4 (±0.1) 3.4 (±0.1) 0.713		(土1.0)	4.6 (\pm 0.1); 4.8 (\pm 0.6)			0.655	
34(+01) 38(+01) 0005 38(+01) 0940		4.3 (±1.0) 0.159	4.5 (±0.1); 4.4 (±1.0)	0.319 4.6 (±0.1);	= 0.1); 4.3 (±0.1)	0.018	
34(+01) 38(+01) 005 38(+01) 0940							
			3.4 (±0.1); 3.0 (±0.1)		3.8 (±0.1); 3.0 (±0.1)	0.000	
pared to average person 4.0 (±0.1) 3.8 (±0.1) 0.048 4.0 (±0.1) 0.153			4.0 (± 0.1) ; 3.6 (± 0.1)		4.0 (± 0.1); 3.7 (±0.1)	0.039	
4.2 (±0.1) 4.4 (±0.1) 0.022 4.4 (±0.1) 0.428			4.2 (± 0.1) ; 4.3 (± 0.1)		4.4 (±0.1); 4.5 (±0.1)	0.493	
Participating in ongoing screening 4.8 (±0.1) 5.2 (±0.1) 0.012 5.1 (±0.1) 0.088 4.9 (±0.1) colt officered 0.012 5.1 (±0.1) 0.038 4.9 (±0.1)	4.9 (±0.1) 101 (±0.3)	5.0 (±0.1) 0.552	4.8 (±0.1); 5.2 (±0.1) 00 (±0.2); 10 1 (±0.2)	0.039 0.134 (±	5.1 (±0.1); 5.0 (±0.1)	0.426	
ion $11.7 (\pm 0.2)$ $12.0 (\pm 0.2)$ 0.095 $12.1 (\pm 0.2)$ 0.0895	10.1 (± 0.2) 10.9 (± 0.2)		7.7 (± 0.2), 10.1 (± 0.2) 11.7 (± 0.2); 10.9 (± 0.2)		= 0.2); 11.1 (±0.2)	0.002	

The reduction in state anxiety within the positive group is consistent with other studies by Brasso *et al* (2010), Parker *et al* (2002) and a more recent study that included measurements pre FIT and also demonstrated significantly higher mean scores and mood disturbance in FIT positives compared to negatives, with a drop in these same parameters 4 months post testing (Laing *et al*, 2014).

FIT positives experienced a significant improvement in the HLoC power domain post colonoscopy, indicating that undergoing such a procedure is perhaps an empowering experience in terms of perceived control over one's health. Indeed, a sense of self-empowerment and self-efficacy has been demonstrated to positively influence cancer screening behaviour, in terms of decision making, intentions and uptake (Consedine *et al*, 2007; McQueen *et al*, 2008; Luszczynska *et al*, 2012).

Positives showed significantly higher doubt in relation to their screening decision. This decreased following colonoscopy, probably associated with removal of apprehension about diagnostic outcome. Positives also reported that they would find it less difficult to participate in ongoing CRC screening, with the intention to continue screening after making an initial decision to screen also being supported by Lewis *et al* (2010).

A contrast was seen in CRC risk perception, with negatives reporting significantly less likelihood of developing CRC in comparison to positives both ARN and at 1 year. In addition, positives reported an increase in seriousness of CRC after colonoscopy. This demonstrated discrepancy is of importance, as higher perceived CRC susceptibility is a positive predictor of higher screening intentions (Azaiza and Cohen, 2008; Dillard *et al*, 2012), while a lower perceived susceptibility is a negative indicator (Wackerbarth *et al*, 2008). This indicates that perhaps negatives require education on their overall CRC risk, with the aim of encouraging participation in future screening.

Limitations. One limitation of this study is the smaller sample size in comparison to other studies. However, outcomes are congruent with other studies in terms of minimal adverse effects on QOL indicators and the transience of anxiety following a positive result.

This study lacks a 'true' baseline (i.e. a measure of outcomes prior to CRC screening). Owing to privacy and confidentiality restrictions, researchers are unable to access the Australian register that stores information and co-ordinates the national CRC screening mail-out. Therefore, there is currently no way of obtaining pre-testing data from participants.

Lastly, the sample comprised predominantly those born in Australian or the United Kingdom and may not represent the impact of CRC screening on different cultural groups. Despite these limitations, the study provides new insights into the psychological impacts of FIT-based CRC screening in Australia.

ACKNOWLEDGEMENTS

This study was funded by the South Australian Government Strategic Health Research Program.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

Australian Bureau of Statistics (2013) *Socio-Economic Indexes for Areas* (*SEIFA*) 2011. ABS Catalogue no. 2033.0.55.001, pp 1–8. Commonwealth of Australia: Canberra.

- Azaiza F, Cohen M (2008) Colorectal cancer screening, intentions, and predictors in Jewish and Arab Israelis: a population-based study. *Health Educ Behav* 35(4): 478–493.
- Basnov M, Kongsved SM, Bech P, Hjollund NH (2009) Reliability of short form-36 in an Internet- and a pen-and-paper version. *Info Health Soc Care* 34(1): 53–58.

Bowel Cancer Screening Pilot Monitoring and Evaluation Steering Committee (2005) A Qualitative Evaluation of Opinions, Attitudes and Behaviours Influencing the Bowel Cancer Screening Pilot Program. Screening Monograph No. 2/2005, p 8. Commonwealth of Australia: Australia.

Bowel Cancer Screening Pilot Monitoring and Evaluation Steering Committee (2005) Australia's Bowel Cancer Screening Pilot and Beyond, Final Evaluation Report. p 67. Commonwealth of Australia: Australia.

Brasso K, Ladelund S, Frederiksen BL, Jorgensen T (2010) Psychological distress following fecal occult blood test in colorectal cancer screening – a population-based study. Scand J Gastroenterol 45(10): 1211–1216.

- Consedine NS, Horton D, Magai C, Kukafka R (2007) Breast screening in response to gain, loss, and empowerment framed messages among diverse, low-income women. *J Health Care Poor Underserved* **18**(3): 550–566.
- Dillard AJ, Ferrer RA, Ubel PA, Fagerlin A (2012) Risk perception measures' associations with behavior intentions, affect, and cognition following colon cancer screening messages. *Health Psych* **31**(1): 106–113.
- Dillman DA, Sinclair MD, Clark JR (1993) Effects of questionnaire length, respondent-friendly design, and a difficult question on response rates for occupant-addressed census mail surveys. *Pub Opin Quart* 57(3): 289–304.
- Edwards P, Roberts I, Clarke M, DiGuiseppi C, Pratap S, Wentz R, Kwan I (2002) Increasing response rates to postal questionnaires: systematic review. *BMJ* **324**(7347): 1183.
- European Commission (2010) European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis, 1st edn. European Union: Luxembourg (Chapter 1).
- Hoff G, Dominitz J (2010) Contrasting US and European approaches to colorectal cancer screening: which is best? *Gut* **59**(3): 407–414.
- Kapidzic A, Korfage IJ, van Dam L, van Roon AH, Reijerink JC, Zauber AG, van Ballegooijen M, Kuipers EJ, van Leerdam ME (2012) Quality of life in participants of a CRC screening program. Br J Canc 107(8): 1295–1301.
- Laing SS, Bogart A, Chubak J, Fuller S, Green BB (2014) Psychological distress after a positive fecal occult blood test result among members of an integrated healthcare delivery system. *Canc Epidemiol Biomarkers Prev* 23(1): 154–159.
- Levy AG, Shea J, Sankey V, Quistberg A, Armstrong K (2006) Measuring perceptions of breast cancer risk. *Canc Epidemiol Biomarkers Prev* 15: 1893–1898.
- Lewis CL, Couper MP, Levin CA, Pignone MP, Zikmund-Fisher BJ (2010) Plans to stop cancer screening tests among adults who recently considered screening. J Gen Intern Med 25(8): 859–864.
- Luszczynska A, Durawa AB, Scholz U, Knoll N (2012) Empowerment beliefs and intention to uptake cervical cancer screening: three psychosocial mediating mechanisms. Wom Health 52(2): 162–181.
- McQueen A, Tiro JA, Vernon SW (2008) Construct validity and invariance of four factors associated with colorectal cancer screening across gender, race, and prior screening. *Canc Epidemiol Biomarkers Prev* 17(9): 2231–2237.
- Niv Y, Bogolavski I, Ilani S, Avni I, Gal E, Vilkin A, Levi Z (2012) Impact of colonoscopy on quality of life. *Eur J Gastroenterol Hepatol* 24(7): 781–786.
- Parker MA, Robinson MH, Scholefield JH, Hardcastle JD (2002) Psychiatric morbidity and screening for colorectal cancer. J Med Screen 9(1): 7–10.
- Pizzo E, Pezzoli A, Stockbrugger R, Bracci E, Vagnoni E, Gullini S (2011) Screenee perception and health-related quality of life in colorectal cancer screening: a review. *Value Health* 14(1): 152–159.
- Ross WA (2010) Colorectal cancer screening in evolution: Japan and the USA. *J Gastroenterol Hepatol* **25**(Suppl 1): S49–S56.
- Sharples LD, Todd CJ, Caine N, Tait S (2000) Measurement properties of the Nottingham Health Profile and the Short Form 36 health status measures in a population sample of elderly people living at home: results from ELPHS. Br J Health Psych 5(Part 3): 217–233.
- Spielberger CD (2010) State-Trait Anxiety Inventory. Corsini Encyclopedia of Psychology. John Wiley and Sons: New Jersey.
- Stalmeier PFM, Roosmalen MS, Verhoef LCG, Hoekstra-Weebers JE, Oosterwijk JC, Moog U, Hoogerbrugge N, van Daal WA (2005) The Decision Evaluation Scales. *Pat Educ Counsel* 57: 286–293.

Taupin D, Chambers SL, Corbett M, Shadbolt B (2006) Colonoscopic screening for colorectal cancer improves quality of life measures: a population-based screening study. *Health Qual Life Outcomes* 4: 82.

Wackerbarth SB, Peters JC, Haist SA (2008) Modelling the decision to undergo colorectal cancer screening: insights on patient preventive decision making. *Med Care* 46(9 Suppl 1): S17–S22.

- Wallston KA, Strudler-Wallston B, DeVellis R (1978) Development of the multidimensional health locus of control (MHLC) scales. *Health Educ Monogr* 6(2): 160–170.
- World Health Organization, International Agency for Research on Cancer (2010) GLOBOCAN 2008. Estimated Cancer Incidence, Mortality, Prevalence and Disability-adjusted life years (DALYs) Worldwide in 2008. Lyon, France.